A molecular crystal form of (S)-3-(2,5-dimethyl-6-(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl)pyrimidin-4-ylamino)-2-(4-methoxyphenylsulfonamido)propanoic acid is characterized by an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 7.44, 14.80, 16.64, and 23.04 ±0.2°. The molecular crystal can be formulated into pharmaceutical composition for treating or controlling diseases resulting from pathological angiogenesis.本發明係有關一種(S)-3-(2,5-二甲基-6-(4-(5,6,7,8-四氫-1,8-啶-2-基)六氫吡啶-1-基)嘧啶-4-基胺基)-2-(4-甲氧基苯基磺醯胺基)丙酸之分子結晶形式，其特徵在於包含7.44、14.80、16.64及23.04±0.2°之2θ角度處之峰的X射線粉末繞射(「XRPD」)譜圖。該分子結晶可經調配為用於治療或控制由病理性血管生成引起之疾病的醫藥組合物。
